|Clinical Trial Title||Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease|
|Trial Status||Open to Enrollment|
|Location||Doctors & Locations|
|Trial Type||Cancer - Adult Oncology|
|Specific Condition||Metastatic Brain Disease|
|Description||This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Fractionated stereotactic radiosurgery delivers multiple, smaller doses of radiation therapy over time. This study may help doctors find out if fractionated stereotactic radiosurgery is better or worse than the usual approach with single fraction stereotactic radiosurgery.
Please contact Legacy Oncology Research for additional study inclusion/exclusion information.
|IRB Number||Central IRB|
|Principal Investigator||Andrew Kee, MD|
|Contact Name||Oncology Clinical Research|